Compare Entegris Inc (ENTG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Merck & Co., Inc. — how do they compare? Entegris Inc trades at $164.01 (market cap $24.78B), while Merck & Co., Inc. trades at $145.74 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 14.2× Entegris Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Merck & Co., Inc. for 98 Days on average.
| ENTG | MRK | |
|---|---|---|
Market Cap | $24.78B | $351.28B |
Volume | 2,648,320 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $184.00 | $156.43 |
52-Week Low | $68.80 | $82.49 |
Typical Hold Time | 41 Days | 98 Days |
Enterprise Value | $27.99B | $398.04B |
Dividend Yield | 0.25% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.
The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
